Professor Chen Xiao Interprets Tarlatamab Second-Line Small Cell Lung Cancer Data and Safety Management

An interview with Professor Chen Xiao focuses on the mechanism, efficacy, and safety of tarlatamab in second-line small cell lung cancer. Its DLL3/CD3 bispecific T-cell engager (TCE) mechanism bypasses MHC-I restriction. In DeLLphi-304, median OS rose from 8.3 months with chemotherapy to 13.6 months, ORR from 20% to 35%, and the risk of death fell by 40%; the Chinese bridging study DeLLphi-307 showed an ORR of 39%.